Guido Tricot

High Impact

Professor

UAMS primary UA Little Rock University of Arkansas

Also affiliated: Leiden University (1981); University of Iowa (2012–2023); University of Maryland, Baltimore (1999–2004); Grant Medical Center (2002); BC Cancer Agency (2013); Arkansas Children's Hospital (1998); University of Minnesota (1983–1985); Hackensack University Medical Center (2003); NewYork–Presbyterian Hospital (2009); Central South University (2023); Radboud University Nijmegen (1984); Emory University (1993); Inserm (1981); Oregon Health & Science University (2007); University of Basel (2005); Medical College of Wisconsin (2003–2018); Cornell University (2009); University of Utah (2008–2019); Rega Institute for Medical Research (1983–1986); Indiana University Hospital (1989–1990); University of Perugia (1983); University of Arkansas Medical Center (1996–2023); Leiden University Medical Center (1981–1982); Universitair Ziekenhuis Leuven (1984–1987); Huntsman Cancer Institute (2009–2019); University of Iowa Hospitals and Clinics (2013–2019); Statistics Belgium (1981); Saint Vincent Health System (2003); University Medical Center (1992); Moffitt Cancer Center (2000); Institut National de Recherche en Santé Publique (2003); Fred Hutch Cancer Center (1997–2013); Acentech (United States) (1998); Central Arkansas Veterans Healthcare System (2001–2002); European Society for Blood and Marrow Transplantation (2009); Cancer Research And Biostatistics (2003–2015); Carver Bible College (2015); Hikma Pharmaceuticals (United Kingdom) (2000); Indiana Cancer Consortium (1988); Dana-Farber Cancer Institute (2003); Platelet BioGenesis (United States) (1998); Indiana University Bloomington (1989–1994); Myeloma UK (2007–2009); Walther Cancer Foundation (1990); University of Applied Management Studies (2024); Cancer Research Center (1990–2025); Winthrop Rockefeller Foundation (2020–2025); Frederick National Laboratory for Cancer Research (1997); Hôtel-Dieu de Paris (1980); Christ Hospital (1993); University of Minnesota Medical Center (1985); Urology of Indiana (1986); System Biosciences (United States) (1995); National Cancer Institute (1997–2013); Hôpital Saint-Louis (1981–2015); Millennium Engineering and Integration (United States) (2005); Center for Cancer Research (1997–1999); John L. McClellan Memorial Veterans Hospital (1994–1997); Avalon Pharma (United States) (2007); Third Xiangya Hospital (2023); Iowa City Public Library (2016); International Myeloma Foundation (2015); Arkansas Department of Agriculture (2000–2002); SWOG Cancer Research Network (2000); U-M Rogel Cancer Center (1999–2004); University of Iowa Holden Comprehensive Cancer Center (2015); Indiana University School of Medicine (1987–1993); Bristol-Myers Squibb (Switzerland) (2001); University of Oklahoma Health Sciences Center (2005); The Ohio State University (2007); Indiana University – Purdue University Indianapolis (1986–1996); Indiana University (1989–1993); University of Baltimore (2000); University of Cincinnati (1991); Zhejiang University (2025); Science Applications International Corporation (United States) (1997); University of Bologna (2006); UCLouvain (1984); Stanford University (2007); KU Leuven (1982–2015)

Faculty Researcher

Internal Med, College of Medicine

97 h-index 715 pubs 36,520 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website Research Group UAMS TRI Profile

OverviewAI-generated summary

Guido Tricot's research focuses on multiple myeloma, a hematologic malignancy. His work investigates the genetic underpinnings of the disease, including cytogenetic alterations that contribute to its complexity and progression. He also explores the role of specific genes, such as TRIP13, in tumor development and the progression of B cell malignancies.

Tricot's laboratory is involved in developing novel therapeutic strategies for multiple myeloma. This includes research into chimeric antigen receptor (CAR) T-cell therapies, specifically bispecific CAR-T cells targeting both BCMA and CD24, and their potential to control myeloma growth. His research also examines the immune microenvironment in multiple myeloma and its precursor stages, utilizing multi-omics approaches to understand these alterations.

Furthermore, his work addresses disparities in access to advanced cancer treatments, such as CAR T-cells and bispecific antibodies, for multiple myeloma patients, examining geographic and racial factors. Tricot also studies the clinical implications of minimal residual disease negativity in multiple myeloma and investigates mechanisms by which genes, like CST6, can suppress osteolytic bone disease associated with the condition. With a significant publication record and high citation count (h-index: 97, total citations: 36,409), Tricot is recognized as a highly cited researcher.

Metrics

h-index: 97
Publications: 715
Citations: 36,520

Selected Publications

Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)

1 citation DOI OpenAlex
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)

2 citations DOI OpenAlex
Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption (2025)

1 citation DOI OpenAlex
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)

5 citations DOI OpenAlex
Identification of Risk Factors for Myeloma Progression in African American Patients (2024)

DOI OpenAlex
The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans (2024)

DOI OpenAlex
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024)

1 citation DOI OpenAlex
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024)

22 citations DOI OpenAlex
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma (2024)

8 citations DOI OpenAlex
Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma (2024)

2 citations DOI OpenAlex
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation (2024)

4 citations DOI OpenAlex
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems (2024)

7 citations DOI OpenAlex
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024)

Nature Communications 46 citations DOI OpenAlex
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up (2023)

8 citations DOI OpenAlex
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma (2023)

17 citations DOI OpenAlex

View all publications on OpenAlex →

Grants & Funding

As listed on this researcher's institutional profile.

Gene expression profiling vs MRD assessment in Myeloma NIH Principal Investigator
UARK 2003-01, Stem Cell Mobilization and Transplantation of Proven and/or Predicted Poor Mobilizers with Mutliple Myeloma AnorMED, Inc. Principal Investigator